Story thread · 3 reports / 3 sources
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
thestar.com · 3h · first report
Acquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assetsYUPELRI® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRRZymeworks to retain…
The coverage
- Zymeworks outlines guidance following Theravance acquisition
seekingalpha.com · 2h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.